Tenofovir Disoproxil Fumarate / Emtricitabine 300mg/200mg Tablet
Recovir-EM 300mg/200mg film-coated Tablets, 30s HDPE bottle. Treatment of HIV-1 infection in combination with other antiretroviral agents
Share Now
Additional Information
Name | Tenofovir Disoproxil Fumarate / Emtricitabine |
Description | Emtricitabine is a nucleoside analogue of cytidine. Tenofovir disoproxil is converted in vivo to tenofovir, a nucleoside monophosphate (nucleotide) analogue of adenosine monophosphate. Both emtricitabine and tenofovir have activity that is specific to human immunodeficiency virus (HIV-1 and HIV-2) and hepatitis B virus. Emtricitabine and tenofovir are phosphorylated by cellular enzymes to form emtricitabine triphosphate and tenofovir diphosphate, respectively. In vitro studies have shown that both emtricitabine and tenofovir can be fully phosphorylated when combined together in cells. Emtricitabine triphosphate and tenofovir diphosphate competitively inhibit HIV-1 reverse transcriptase, resulting in DNA chain termination. Both emtricitabine triphosphate and tenofovir diphosphate are weak inhibitors of mammalian DNA Polymerases |
Active Ingredient | Tenofovir Disoproxil Fumarate / Emtricitabine |
Indication | Tenofovir disoproxil fumarate / Emtricitabine tablets is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults and treatment of HIV-1 infected adolescents. Additionally, it is also indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents at high risk. |
Strengths | 300mg/200mg Tablet |
Business Partner | Mylan |
Origin | India |
Related Products
Related products
Caspovitae (CASPOFUNGIN)
Rated 0 out of 5Tigevitae (TIGECYCLINE)
Rated 0 out of 5Lopinavir/Ritonavir 200mg/50mg Tablets (Alltera)
Rated 0 out of 5Deltyba – 50mg (DELAMANID)
Rated 0 out of 5
Disclaimer
Pharma Solution is the marketing agent and Distributor for the listed products for the Gulf and MENA region. The products are either registered and approved by the respective local health authority or contracted by the MAH to supply to the end users on a named patient basis. Some products such as Orphan drugs, rare diseases medicines are imported based on special import permits and as per need of the Hospitals in compliance with full documentation.